TICKERNERD
Menu
QNCXQNCXHealthcare · Biotechnology

QNCX Stock Forecast: Quince Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 14 Aug 2026
$34

The 6 Wall Street analysts covering Quince Therapeutics, Inc. hold a median 12-month price target of $81 — +138.0% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 24 of 100 as at 15 Aug 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$34.6M
Ticker Nerd rank
24 / 100
Median analyst target
$81
Analysts covering
6
Ticker Nerd rank

QNCX stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Quince Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 15 Aug 2026
24 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
85
Accruals
80
Issuance
57
Growth
40
Revisions
27
Momentum
19
Volatility
17
Value
17
Quality
15

Size (85): Smaller than most of the companies we track.

Quality (15): Profits are thin or unreliable for the size of the business, or they are not turning into cash.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

QNCX stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on QNCX, reported as data — targets and ratings, the market's view beside the model's.

We don’t hold enough price history for this company yet.

What Wall Street says6 analysts
4 Buy2 Hold0 Sell
Low $70Median $81High $99

The green dot is the last close — the median target sits +138.0% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
29 July 2026OppenheimerInitiatesOutperform$82
24 June 2026Leerink PartnersInitiatesOutperform$4.00
24 June 2026Leerink PartnersInitiatesOutperform—
23 June 2026Cantor FitzgeraldInitiatesOverweight$4.00
23 June 2026Cantor FitzgeraldInitiatesOverweight—
30 Jan 2026CitizensDowngradeMarket Perform—
30 Jan 2026D. Boral CapitalDowngradeHold—
29 Jan 2026D. Boral CapitalMaintainsBuy—
15 Dec 2025D. Boral CapitalMaintainsBuy—
13 Nov 2025D. Boral CapitalMaintainsBuy—
26 Sept 2025D. Boral CapitalMaintainsBuy—
15 Aug 2025D. Boral CapitalMaintainsBuy—
12 Aug 2025JMP SecuritiesMaintainsMarket Outperform—
5 Aug 2025JMP SecuritiesInitiatesMarket Outperform—
17 July 2025D. Boral CapitalMaintainsBuy—
13 June 2025D. Boral CapitalMaintainsBuy—
4 June 2025D. Boral CapitalMaintainsBuy—
25 Mar 2025D. Boral CapitalMaintainsBuy—
24 Mar 2025OppenheimerInitiatesOutperform—
5 Feb 2025D. Boral CapitalMaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. QNCX appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

QNCX analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
0
Fundamentals

Quince Therapeutics, Inc. (QNCX) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−0.1×

Cheaper than 77% of US stocks

Price / sales
—
Price / book
1.5×

Cheaper than 57% of US stocks

EV / EBITDA
−0.2×

Cheaper than 62% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−192.9%

Higher than 7% of US stocks

Return on assets
−45.4%

Higher than 9% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

QNCX vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
QNCXQuince Therapeutics, Inc.$34.6M
24
LTRNLantern Pharma, Inc.$33.8M
58
ATNMActinium Pharmaceuticals, Inc.$32.6M
70
BYSIBeyondSpring, Inc.$34.5M
20
NNVCNanoViricides, Inc.$35.1M
59
LITSLite Strategy, Inc.$31.6M
31
ESLAEstrella Immunopharma, Inc.$30.4M
25

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Quince Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest QNCX news & analysis

Quince Therapeutics Reports Second Quarter 2026 Financial Results and Corporate Update

GlobeNewsWire · 14 Aug 2026positive

Quince Therapeutics reported its second quarter 2026 financial results and issued a corporate update. The company completed its acquisition of Orphai Therapeutics, which added LAM-001, an inhaled formulation of rapamycin for treating multiple serious, underserved pulmonary diseases, to its pipeline.

Why it matters — QNCX watchers would care because the completed Orphai acquisition expands the company's pipeline with a new inhaled therapeutic candidate targeting serious pulmonary diseases.

FAQ

Frequently asked questions about QNCX stock

What is the QNCX stock price forecast for 2026-2027?

The 6 Wall Street analysts covering Quince Therapeutics, Inc. have a median 12-month price target of $81, with estimates ranging from $70 to $99. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is QNCX stock a buy right now?

Of the 6 analysts covering Quince Therapeutics, Inc., 4 rate it a Buy, 2 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Quince Therapeutics, Inc. 24 out of 100 across roughly 4,600 US stocks as at 15 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank QNCX?

As at 15 Aug 2026, Quince Therapeutics, Inc. ranks 24 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (85 of 100).

Will QNCX stock go up?

No one can know that. What the data says: the median 12-month target from 6 analysts implies +138.0% from the last close, and Ticker Nerd's factor model ranks Quince Therapeutics, Inc. 24 out of 100 as at 15 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the QNCX stock forecast for 2030?

No analyst covering Quince Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for QNCX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $70 to $99 over the next 12 months.

What does Quince Therapeutics, Inc. do?

Quince Therapeutics Inc. is a biotechnology company focused on discovering and developing innovative therapies aimed at treating medical conditions with a significant unmet need.

What is the latest news on QNCX?

The most recent item we track (GlobeNewsWire, 14 Aug 2026): "Quince Therapeutics Reports Second Quarter 2026 Financial Results and Corporate Update". Quince Therapeutics reported its second quarter 2026 financial results and issued a corporate update. The company completed its acquisition of Orphai Therapeutics, which added LAM-001, an inhaled formulation of rapamycin for treating multiple serious, underserved pulmonary diseases, to its pipeline.

Company

About Quince Therapeutics, Inc.

Quince Therapeutics Inc. is a biotechnology company focused on discovering and developing innovative therapies aimed at treating medical conditions with a significant unmet need. By leveraging advanced technologies, the company dedicates its resources towards creating novel therapeutics that address the underlying mechanisms of diseases. Quince Therapeutics operates within the pharmaceutical and biotechnology sector, impacting both the healthcare and life sciences industries. The company's research and development initiatives are crucial in the realm of rare diseases and complex medical disorders, where few effective treatments are currently available. Through strategic partnerships and collaborations, Quince Therapeutics endeavours to translate scientific breakthroughs into practical, patient-centric solutions. In the broader financial market, Quince Therapeutics plays an integral role in driving innovation and progress within the healthcare sector, contributing to advancements that can lead to better patient outcomes and quality of life improvements worldwide. As a biotechnology entity, Quince Therapeutics is integral in the ongoing efforts to bring cutting-edge therapies from concept to clinical reality.

CEO Dr. Dirk Thye M.D. · 38 employees · United States · https://quincetx.com